{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:47:20Z","timestamp":1792734440140,"version":"4.5.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"UC Brain Tumor Center and the Holly and David Cook Family Brain Tumor Research Endowment"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA120813"],"award-info":[{"award-number":["CA120813"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS120547"],"award-info":[{"award-number":["NS120547"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA221747"],"award-info":[{"award-number":["CA221747"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oligodendroglioma is a primary central nervous system tumor classified by the presence of isocitrate dehydrogenase (IDH) mutations and codeletion of 1p\/19q. A lack of faithful preclinical model systems for this disease has limited progress in understanding the biology of this genetically unique subtype of adult diffuse-type glioma and in developing new effective therapies. To address this unmet need, we sought to establish a mouse model that faithfully recapitulates the genetic and phenotypic features of human IDH-mutant 1p\/19q-codeleted oligodendroglioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed in utero electroporation to introduce distinct combinations of genetic alterations and evaluated their potential to form tumors. Resulting tumors were characterized by histology, metabolite profiling, RNA-sequencing and single-cell RNA-sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified co-expression of IDH1R132H and PIK3CAE545K together with loss of Cic, Fubp1, and Cdkn2a (termed OligoCdkn2a) as the optimal genetic combination to drive fully penetrant tumors that histologically resemble human grade III IDH-mutant 1p\/19q-codeleted oligodendroglioma. Substituting Cdkn2a loss with Trp53 deletion decreased latency and shifted tumors toward high-grade astrocytoma histology. OligoCdkn2a tumors displayed metabolic and transcriptional changes associated with IDH and CIC mutations, and single-cell sequencing identified a bias toward oligodendrocyte differentiation compared to an IDH wild-type glioblastoma mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To our knowledge, OligoCdkn2a tumors represent the first autochthonous, genetically engineered mouse model to recapitulate the genetic, histological, and transcriptional features of human IDH-mutant 1p\/19q-codeleted oligodendrogliomas. This model will provide a valuable platform to further dissect mechanisms of tumorigenesis and test novel therapeutic strategies for this molecularly distinct glioma subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag228","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:25:05Z","timestamp":1789651505000},"source":"Crossref","is-referenced-by-count":1,"title":["Murine modeling of IDH-mutant 1p\/19q-codeleted oligodendroglioma reveals genotype-specific phenotypes"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9780-1506","authenticated-orcid":false,"given":"Ipsita G","family":"Kundu","sequence":"first","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3229-2276","authenticated-orcid":false,"given":"Nicolas","family":"Toro","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1073-916X","authenticated-orcid":false,"given":"Aaron Y","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]},{"name":"The Cure Starts Now Foundation Brain Tumor Center, Division of Oncology, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7719-1920","authenticated-orcid":false,"given":"Jaldeep","family":"Langhnoja","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0070-1870","authenticated-orcid":false,"given":"Rithvik V","family":"Ayyagari","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6401-0740","authenticated-orcid":false,"given":"James C","family":"Cronk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]},{"name":"The Cure Starts Now Foundation Brain Tumor Center, Division of Oncology, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-6707","authenticated-orcid":false,"given":"Sarah M","family":"Reel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]},{"name":"The Cure Starts Now Foundation Brain Tumor Center, Division of Oncology, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phonepasong","family":"Arounleut","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-287X","authenticated-orcid":false,"given":"Luis E","family":"Tron Esqueda","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Physiology, and Neurobiology, College of Medicine, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Fuller","sequence":"additional","affiliation":[{"name":"Department of Pathology, SUNY Upstate Medical University , Syracuse, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-3109","authenticated-orcid":false,"given":"Pavithra","family":"Viswanath","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-8695","authenticated-orcid":false,"given":"Amy B","family":"Heimberger","sequence":"additional","affiliation":[{"name":"Malnati Brain Tumor Institute, Northwestern University , Chicago, Illinois,","place":["USA"]},{"name":"Department of Neurological Surgery, Northwestern University , Chicago, Illinois,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-9992","authenticated-orcid":false,"given":"Craig M","family":"Horbinski","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Jacksonville, Florida,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4771-4003","authenticated-orcid":false,"given":"Timothy N","family":"Phoenix","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati , Cincinnati, Ohio,","place":["USA"]},{"name":"Division of Research in Patient Services, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2026101601463902000_noag228-B1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026101601463902000_noag228-B2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026101601463902000_noag228-B3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","article-title":"cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas","volume":"139","author":"Brat","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2026101601463902000_noag228-B4","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"key":"2026101601463902000_noag228-B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026101601463902000_noag228-B6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","article-title":"Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up","volume":"8","author":"Douw","year":"2009","journal-title":"Lancet Neurol"},{"key":"2026101601463902000_noag228-B7","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/neuonc\/noaf172","article-title":"Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation","volume":"27","author":"Boele","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026101601463902000_noag228-B8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat Med"},{"key":"2026101601463902000_noag228-B9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026101601463902000_noag228-B10","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S1470-2045(25)00472-3","article-title":"Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"26","author":"Cloughesy","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026101601463902000_noag228-B11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"2026101601463902000_noag228-B12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"key":"2026101601463902000_noag228-B13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/neuonc\/nox183","article-title":"Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications","volume":"20","author":"Malta","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026101601463902000_noag228-B14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"2026101601463902000_noag228-B15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"2026101601463902000_noag228-B16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature16490","article-title":"Insulator dysfunction and oncogene activation in IDH mutant gliomas","volume":"529","author":"Flavahan","year":"2016","journal-title":"Nature"},{"key":"2026101601463902000_noag228-B17","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1016\/j.cell.2023.06.022","article-title":"Modeling epigenetic lesions that cause gliomas","volume":"186","author":"Rahme","year":"2023","journal-title":"Cell"},{"key":"2026101601463902000_noag228-B18","doi-asserted-by":"publisher","first-page":"e20200924","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J Exp Med"},{"key":"2026101601463902000_noag228-B19","doi-asserted-by":"publisher","first-page":"8981","DOI":"10.1158\/0008-5472.CAN-10-1666","article-title":"Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1","volume":"70","author":"Seltzer","year":"2010","journal-title":"Cancer Res"},{"key":"2026101601463902000_noag228-B20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cell.2018.08.038","article-title":"Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma","volume":"175","author":"McBrayer","year":"2018","journal-title":"Cell"},{"key":"2026101601463902000_noag228-B21","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ccell.2015.11.006","article-title":"Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion","volume":"28","author":"Tateishi","year":"2015","journal-title":"Cancer Cell"},{"key":"2026101601463902000_noag228-B22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00401-015-1424-1","article-title":"Oligodendroglioma: pathology, molecular mechanisms and markers","volume":"129","author":"Wesseling","year":"2015","journal-title":"Acta Neuropathol"},{"key":"2026101601463902000_noag228-B23","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat","year":"2015","journal-title":"N Engl J Med"},{"key":"2026101601463902000_noag228-B24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40478-017-0422-z","article-title":"Genetic and epigenetic stability of oligodendrogliomas at recurrence","volume":"5","author":"Aihara","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"2026101601463902000_noag228-B25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41698-018-0067-9","article-title":"Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways","volume":"2","author":"Halani","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"2026101601463902000_noag228-B26","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1126\/science.1210557","article-title":"Mutations in CIC and FUBP1 contribute to human oligodendroglioma","volume":"333","author":"Bettegowda","year":"2011","journal-title":"Science"},{"key":"2026101601463902000_noag228-B27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00401-012-0993-5","article-title":"CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas","volume":"123","author":"Sahm","year":"2012","journal-title":"Acta Neuropathol"},{"key":"2026101601463902000_noag228-B28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40478-022-01372-1","article-title":"Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma","volume":"10","author":"Wong","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"2026101601463902000_noag228-B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai8478","article-title":"Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq","volume":"355","author":"Venteicher","year":"2017","journal-title":"Science"},{"key":"2026101601463902000_noag228-B30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccr.2005.07.004","article-title":"Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma","volume":"8","author":"Zhu","year":"2005","journal-title":"Cancer Cell"},{"key":"2026101601463902000_noag228-B31","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41467-018-03731-w","article-title":"Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling","volume":"9","author":"Oldrini","year":"2018","journal-title":"Nat Commun"},{"key":"2026101601463902000_noag228-B32","doi-asserted-by":"publisher","first-page":"e148990","DOI":"10.1172\/jci.insight.148990","article-title":"Immune landscape of a genetically engineered murine model of glioma compared with human glioma","volume":"7","author":"Zamler","year":"2022","journal-title":"JCI Insight"},{"key":"2026101601463902000_noag228-B33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ccell.2022.07.011","article-title":"De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma","volume":"40","author":"Shi","year":"2022","journal-title":"Cancer Cell"},{"key":"2026101601463902000_noag228-B34","doi-asserted-by":"publisher","first-page":"eabh3243","DOI":"10.1126\/sciadv.abh3243","article-title":"G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy","volume":"7","author":"Alghamri","year":"2021","journal-title":"Sci Adv"},{"key":"2026101601463902000_noag228-B35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1101\/gad.294991.116","article-title":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","volume":"31","author":"Amankulor","year":"2017","journal-title":"Genes Dev"},{"key":"2026101601463902000_noag228-B36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1126\/science.abj2890","article-title":"A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation","volume":"378","author":"Yanchus","year":"2022","journal-title":"Science"},{"key":"2026101601463902000_noag228-B37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ccell.2016.08.017","article-title":"Expression of Idh1(R132H) in the murine subventricular zone stem cell niche recapitulates features of early gliomagenesis","volume":"30","author":"Bardella","year":"2016","journal-title":"Cancer Cell"},{"key":"2026101601463902000_noag228-B38","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.celrep.2018.03.133","article-title":"Mutant IDH1 promotes glioma formation in vivo","volume":"23","author":"Philip","year":"2018","journal-title":"Cell Rep"},{"key":"2026101601463902000_noag228-B39","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1158\/0008-5472.CAN-15-0840","article-title":"IDH1 mutation induces reprogramming of pyruvate metabolism","volume":"75","author":"Izquierdo-Garcia","year":"2015","journal-title":"Cancer Res"},{"key":"2026101601463902000_noag228-B40","doi-asserted-by":"publisher","first-page":"7391","DOI":"10.1038\/ncomms8391","article-title":"Somatic CRISPR\/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling","volume":"6","author":"Zuckermann","year":"2015","journal-title":"Nat Commun"},{"key":"2026101601463902000_noag228-B41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40170-018-0177-4","article-title":"Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities","volume":"6","author":"Garrett","year":"2018","journal-title":"Cancer Metab"},{"key":"2026101601463902000_noag228-B42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/neuonc\/noac207","article-title":"Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions","volume":"25","author":"Miller","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026101601463902000_noag228-B43","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1073\/pnas.1019393108","article-title":"Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome","volume":"108","author":"Reitman","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101601463902000_noag228-B44","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","article-title":"Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis","volume":"184","author":"Mathewson","year":"2021","journal-title":"Cell"},{"key":"2026101601463902000_noag228-B45","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","article-title":"Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes","volume":"181","author":"Friebel","year":"2020","journal-title":"Cell"},{"key":"2026101601463902000_noag228-B46","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","article-title":"T-cell dysfunction in glioblastoma: applying a new framework","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026101601463902000_noag228-B47","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9: SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"key":"2026101601463902000_noag228-B48","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41467-019-09949-6","article-title":"Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors","volume":"10","author":"Ahmad","year":"2019","journal-title":"Nat Commun"},{"key":"2026101601463902000_noag228-B49","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1158\/0008-5472.CAN-17-1018","article-title":"Cic loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation","volume":"77","author":"Yang","year":"2017","journal-title":"Cancer Res"},{"key":"2026101601463902000_noag228-B50","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/neuonc\/noz216","article-title":"Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas","volume":"22","author":"Drumm","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026101601463902000_noag228-B51","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1016\/j.molcel.2023.07.002","article-title":"FUBP1 is a general splicing factor facilitating 3\u2019 splice site recognition and splicing of long introns","volume":"83","author":"Ebersberger","year":"2023","journal-title":"Mol Cell"},{"key":"2026101601463902000_noag228-B52","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41586-026-10612-6","article-title":"Acquired genetic and cell-state changes in IDH-mutant glioma progression","volume":"655","author":"Johnson","year":"2026","journal-title":"Nature"},{"key":"2026101601463902000_noag228-B53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s43018-024-00865-3","article-title":"Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas","volume":"6","author":"Wu","year":"2025","journal-title":"Nat Cancer"},{"key":"2026101601463902000_noag228-B54","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ccell.2024.03.008","article-title":"Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma","volume":"42","author":"Spitzer","year":"2024","journal-title":"Cancer Cell"},{"key":"2026101601463902000_noag228-B55","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41467-024-44932-w","article-title":"Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas","volume":"15","author":"Hariharan","year":"2024","journal-title":"Nat Commun"},{"key":"2026101601463902000_noag228-B56","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI90644","article-title":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"2026101601463902000_noag228-B57","doi-asserted-by":"publisher","first-page":"eadl6173","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"key":"2026101601463902000_noag228-B58","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.abj5104","article-title":"Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function","volume":"377","author":"Notarangelo","year":"2022","journal-title":"Science"},{"key":"2026101601463902000_noag228-B59","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-17-3855","article-title":"D-2-hydroxyglutarate is an intercellular mediator in IDH-mutant gliomas inhibiting complement and T cells","volume":"24","author":"Zhang","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag228\/71189015\/noag228.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag228\/71189015\/noag228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:46:43Z","timestamp":1792129603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag228\/8812273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag228","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"noag228"}}